Thumbs Up/Thumbs Down: The FDA backs an­oth­er R&D scheme, Kite shows its speed while Eli Lil­ly and As­tra stum­ble again

 
End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE